Preclinical studies have identified inhibition of CXCL-2/CXCR2 as promising therapeutic strategy for inhibiting tumor progression and metastasis: developed drugs include small inhibitors targeting CXCR2 (such as AZD5069 and reparixin), CXCL-2 expression (such as miRNA MIR-532-5p) and function (such as inhibitors of signaling pathway), and anti-CXCL-2 mAbs [259]. The gene discussed is CXCR2; the disease is neoplasm.